Healthcare / BiotechnologyNasdaqCM
$2.79
-0.06 (-2.11%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-28.4M · quality 69.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
35/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$256M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-59.7%
↓Gross Margin
N/A
•Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.79x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-36.1M · FCF $-28.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Net Income | $-36.1M | $-36.1M | $-26.7M | $-24.0M | $-14.8M | $-10.5M | $6.6M |
| EBITDA | $-39.7M | $-39.7M | $-29.9M | $-25.1M | $-14.9M | $-10.5M | — |
| EPS | -0.38 | -0.38 | -0.46 | -1.50 | -0.93 | -3.69 | -3.96 |
| Balance Sheet | |||||||
| Debt/Equity | 0.00 | 0.00 | 0.00 | — | 0.00 | — | — |
| Current Ratio | 8.96 | 8.96 | — | — | — | — | — |
| Cash Flow | |||||||
| Free Cash Flow | $-28.4M | $-28.4M | $-29.3M | $-21.0M | $-14.1M | $-8.8M | — |
| Returns | |||||||
| ROE | -59.7% | -59.7% | -28.1% | -201.9% | -42.7% | -21.7% | -39.3% |
| Valuation | |||||||
| P/B | 4.39 | 4.39 | 0.77 | 1.60 | 0.36 | — | — |
| Growth & Yield | |||||||
| EPS Growth | 17.4% | 17.4% | 69.3% | -61.3% | — | 6.8% | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+383.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.46 → -0.38
Residual
+383.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.